


# PRODUCT INFORMATION



## Brequinar

Item No. 24445

**CAS Registry No.:** 96187-53-0  
**Formal Name:** 6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic acid  
**Synonym:** NSC 368390  
**MF:** C<sub>23</sub>H<sub>15</sub>F<sub>2</sub>NO<sub>2</sub>  
**FW:** 375.4  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 252, 324 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Brequinar is supplied as a crystalline solid. A stock solution may be made by dissolving the brequinar in the solvent of choice. Brequinar is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of brequinar in these solvents is approximately 0.2, 5, and 2 mg/ml, respectively.

Brequinar is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, brequinar should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Brequinar has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Brequinar is an inhibitor of dihydroorotate dehydrogenase (DHODH; IC<sub>50</sub> = ~20 nM), the enzyme that converts dihydroorotate to orotate during *de novo* pyrimidine synthesis.<sup>1</sup> Brequinar is selective for DHODH over a panel of greater than 400 kinases at 100 nM. It induces differentiation of ER-HoxA9, U937, and THP-1 cells *in vitro* (ED<sub>50</sub>s = ~1 μM) and of tumor cells in a THP-1 mouse xenograft model when administered at doses of 15 mg/kg three times daily and 5 mg/kg per day. It also reduces tumor growth in THP-1, HL-60, and MOLM-13 mouse xenograft models. In a retroviral transduction mouse model of HoxA9 + Meis1 acute myeloid leukemia (AML), brequinar induces differentiation of bone marrow leukemic cells and increases survival.

### Reference

1. Sykes, D.B., Kfoury, Y.S., Mercier, F.E., *et al.* Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. *Cell*. **167**(1), 171-186 (2016).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/06/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM